Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose human mass balance and pharmacokinetics study of 14C-labeled GRC 4039 sodium in healthy male volunteers
NL-OMON37911Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of revamilast in Not applicable, sponsored by Glenmark Pharmaceuticals SA. Primary endpoints: Pharmacokinetics of total radioactivity in plasma and urine, Pharmacokinetics of parent GRC 4039 and metabolite GRC 4037 and 5 more. Started Jan 2012; status: active, not recruiting.
02
Drugs
revamilast
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON37911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37911.